ARTV · Artiva Biotherapeutics, Inc.
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-08-06 | Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights |
| 2026-07-17 | Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-23 | Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference |
| 2026-06-08 | Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today |
| 2026-05-28 | Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference |
| 2026-05-19 | Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases |
| 2026-05-19 | Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development |
| 2026-05-08 | Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants |
| 2026-05-08 | Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights |
| 2026-05-08 | Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026 |
| 2026-04-08 | Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference |
| 2026-03-10 | Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights |
| 2026-02-25 | Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference |
| 2026-02-24 |
Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) - Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Thad Huston as Chief Financial Officer. Mr. Huston brings proven expertise in capital allocation, operational execution and global commercialization to support Artiva as it advances AlloNK in autoimmune diseases and continues building an organization positioned for long-term value creation. “We are delighted to welcome Thad to Artiva as he brings strong late-stage development and commercial expertise to our leadership team,” said Fred Aslan, M.D., president and chief executive officer of Artiva Biotherapeutics. “AlloNK has the potential to deliver deep B-cell depletion with biologics-like convenience. This is an important time for Artiva as we prepare to receive feedback from the |
| 2026-02-19 |
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors
SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) - Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Elaine Sorg to its Board of Directors. Ms. Sorg brings more than 35 years of executive leadership and commercial experience in the biopharmaceutical industry to Artiva, including leading the commercialization of major immunology therapies such as HUMIRA ® (adalimumab) and RINVOQ ® (upadacitinib) for rheumatoid arthritis. “We are thrilled to welcome Elaine to Artiva’s board at such an important time for the company,” said Fred Aslan, M.D., president and chief executive officer of Artiva Biotherapeutics. “Elaine brings deep experience building and scaling biopharmaceutical companies and launching innovative therapies. Her strategic perspective will be invaluable as we prepare to |
| 2026-01-21 |
Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL
SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) - Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings) from February 4 – 7, 2026, in Salt Lake City, Utah highlighting the cost-effectiveness of AlloNK in a community rheumatology practice and continued durability of AlloNK in Non-Hodgkin Lymphoma (NHL). The following abstracts will be presented as poster presentations at the 2026 Tandem Meetings: Poster ID: 440 AB-101, an Off-the-Shelf NK Cell Therapy Administered in an Outpatient Community Rheumatology Practice, Is More Cost-Effective Than CAR-T Treatments for Rheumatologic Diseases Poster Session: Health Services and Barriers to Access Date / Time: Thursday, February 5, 2026, at 6:30 pm MST |
Past events
Source: https://investors.artivabio.com/overview/default.aspx